LON:TCF Theracryf (TCF) Share Price, News & Analysis GBX 0.23 -0.02 (-6.12%) As of 05/15/2026 12:25 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About Theracryf Stock (LON:TCF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Theracryf alerts:Sign Up Key Stats Today's Range 0.23▼ 0.2650-Day Range 0.19▼ 0.2652-Week Range 0.18▼ 0.30Volume50.42 million shsAverage Volume6.80 million shsMarket Capitalization£4.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview TheraCryf plc is a biotechnology company developing new medicines for addiction and other disorders of the brain, areas of significant unmet medical need within central nervous system (CNS) disorders. The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders. The programme is heavily de-risked, demonstrates superior selectivity and high receptor occupancy, and is fully funded through to clinical readiness, with regulatory submissions targeted for 2026. TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01. TheraCryf operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with larger pharmaceutical or biotechnology companies. Read More Receive TCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theracryf and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TCF Stock News HeadlinesTheraCryf appoints new board member, issues optionsMay 2, 2025 | uk.investing.comTheracryf Plc (TCF.L)January 18, 2025 | ca.finance.yahoo.comYour book attachedBill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It outlines the approach he developed after losing a small fortune on complex strategies. The book covers a straightforward technique that he says consistently outperforms complicated methods, including how to evaluate any trade in under 10 minutes.May 16 at 1:00 AM | Profits Run (Ad)Theracryf PLC Share Chat (TCF)January 13, 2025 | lse.co.ukSee More Headlines TCF Stock Analysis - Frequently Asked Questions How have TCF shares performed this year? Theracryf's stock was trading at GBX 0.18 on January 1st, 2026. Since then, TCF stock has increased by 25.7% and is now trading at GBX 0.23. How were Theracryf's earnings last quarter? Theracryf Plc (LON:TCF) issued its quarterly earnings data on Wednesday, December, 3rd. The company reported ($6.00) earnings per share for the quarter. Theracryf had a negative net margin of 792.17% and a negative trailing twelve-month return on equity of 37.30%. How do I buy shares of Theracryf? Shares of TCF stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Company Calendar Last Earnings12/03/2025Today5/16/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryBanking Current SymbolLON:TCF CIKN/A Webtheracryf.com Phone44-1625-315-090FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£5.45 million Net Margins-792.17% Pretax MarginN/A Return on Equity-37.30% Return on Assets-48.26% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 0.85 per share Price / Book0.27Miscellaneous Outstanding Shares2,148,964,000Free FloatN/AMarket Cap£4.94 million OptionableN/A Beta1.40 10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (LON:TCF) was last updated on 5/16/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theracryf Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Theracryf With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
